Intervention to Educate and Improve Underrepresented Populations' Participation in Clinical Trials
2 other identifiers
interventional
188
1 country
1
Brief Summary
This proposal aims to leverage ongoing community outreach efforts and the Cancer Center's aims to improve recruitment to clinical trials by educating the catchment and making referrals to engage current UCCC patients not taking advantage of available CTs at this institution and affiliated hospitals. The Cancer Prevention and Control Program within UCCC works to develop and evaluate novel approaches to primary prevention, disseminate preventative interventions in population-based settings, and to improve health services delivery and outcomes for cancer patients and survivors. A primary emphasis is placed on those from underrepresented populations, including Hispanics, residents of outlying rural areas, and those in areas of poverty. Efforts to meet the Cancer Center's priorities include interventions to promote awareness and recruitment of eligible patients to available CTs in the catchment area (the state of Colorado).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable cancer
Started Nov 2020
Typical duration for not_applicable cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 24, 2020
CompletedFirst Submitted
Initial submission to the registry
April 26, 2021
CompletedFirst Posted
Study publicly available on registry
April 28, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 5, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 5, 2024
CompletedMay 8, 2025
May 1, 2025
3.7 years
April 26, 2021
May 5, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Change in knowledge and understanding of and intent to participate in Clinical Trials (CTs)
Using questionnaires to measure the change in knowledge of and understanding and intent to participate in CTs
36 months
Number of patients referred, screened, and enrolled into cancer related therapeutic CTs
Monitoring the number of referrals to and enrollment in CTs will help determine effectiveness of educational materials.
36 months
Secondary Outcomes (2)
Change in number of underrepresented patients participating in cancer related therapeutic CTs
36 months
Identify relationships between sociodemographic variables and the attitudes towards CTs
36 months
Other Outcomes (4)
PN-referred persons screened for cancer related therapeutic CTS;
36 months
PN-referred persons enrolled in related therapeutic CTS;
36 months
connected to care services such as health insurance, treatment assistance programs
36 months
- +1 more other outcomes
Study Arms (1)
Underrepresented Population
EXPERIMENTALA primary emphasis is placed on those from underrepresented populations, including Hispanics, residents of outlying rural areas, and those in areas of poverty
Interventions
The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
Eligibility Criteria
You may qualify if:
- Provision to sign and date the consent form.
- Stated willingness to comply with all study procedures and be available for the duration of the study.
- Be over 18 years old
- English and/or Spanish Speaking
You may not qualify if:
- Individuals who do not meet eligibility criteria, including individuals who do not speak English or Spanish \[at the discretion of the CHE or PN upon recruitment\];
- Decisionally-challenged adults with cognitive or personality impairment or due to intoxication (alcohol or drugs) that might interfere with their ability to consent or participate in the study \[at the discretion of the CHE or PN upon recruitment\];
- Individuals from vulnerable populations (e.g., inmates, homeless, pregnant women, and those with auditory impairment \[at the discretion of the CHE or PN upon recruitment\].
- Individuals under the age of 18 years.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Colorado, Denverlead
- National Cancer Institute (NCI)collaborator
Study Sites (1)
University of Colorado Hospital
Aurora, Colorado, 80045, United States
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Evelinn Borrayo, MD
University of Colorado, Denver
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 26, 2021
First Posted
April 28, 2021
Study Start
November 24, 2020
Primary Completion
August 5, 2024
Study Completion
August 5, 2024
Last Updated
May 8, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share